Effects of Antenatal Exposure to Magnesium Sulfate on Neuroprotection and Mortality in Preterm Infants
- 1 August 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 114 (2), 354-364
- https://doi.org/10.1097/aog.0b013e3181ae98c2
Abstract
OBJECTIVE: To review the evidence regarding neuroprotective effects of antenatal exposure to magnesium sulfate. DATA SOURCES: We conducted database searches of MEDLINE, the Cochrane Library and Controlled Trials Register, as well as the ClinicalTrials.gov and International Clinical Trials Register websites. Bibliographies of all relevant articles were reviewed. METHODS OF STUDY SELECTION: Randomized controlled trials comparing magnesium sulfate with placebo/other treatment in patients at risk of preterm delivery were evaluated for inclusion and methodological quality. The primary outcome was death or cerebral palsy by 18–24 months corrected age. Secondary outcomes were death, cerebral palsy, moderate–severe cerebral palsy, and death or moderate–severe cerebral palsy. Separate analyses were performed according to the gestational age (GA) at randomization (less than 32 to 34 weeks and less than 30 weeks) and for studies in which magnesium sulfate was used exclusively for fetal neuroprotection. TABULATION, INTEGRATION, AND RESULTS: Five randomized controlled trials were included (5,235 fetuses/infants). When analyzed by GA at randomization, in utero exposure to magnesium sulfate at less than 32–34 weeks did not reduce the rate of death or cerebral palsy (relative risk [RR] 0.92, 95% confidence interval [CI] 0.83–1.03). However, cerebral palsy (RR 0.70, 95% CI 0.55–0.89), moderate–severe cerebral palsy (RR 0.60, 95% CI 0.43–0.84), and death or moderate–severe cerebral palsy were significantly reduced, without an evident increase in the risk of death (RR 1.01, 95% CI 0.89–1.14). Similar results were obtained when the GA at randomization was less than 30 weeks. When only neuroprotection trials (four trials, 4,324 fetuses/infants) are analyzed, in utero exposure to magnesium sulfate additionally reduced the primary outcome of death or cerebral palsy. The number needed to treat to prevent one case of cerebral palsy among those who survive until age 18–24 months is 46 (95% CI 26–187) in infants exposed to magnesium sulfate in utero before 30 weeks, and 56 (95% CI 34–164) in infants exposed to magnesium sulfate in utero before 32 to 34 weeks. CONCLUSION: Fetal exposure to magnesium sulfate in women at risk of preterm delivery significantly reduces the risk of cerebral palsy without increasing the risk of death.This publication has 21 references indexed in Scilit:
- Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetusEmergencias, 2009
- A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral PalsyThe New England Journal of Medicine, 2008
- Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul à deux ans : résultats de l’essai prospectif multicentrique contre placebo PREMAGGynécologie Obstétrique & Fertilité, 2008
- Prevalence of Cerebral Palsy in 8-Year-Old Children in Three Areas of the United States in 2002: A Multisite CollaborationPEDIATRICS, 2008
- The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre‐eclampsia. Outcome for children at 18 monthsBJOG: An International Journal of Obstetrics and Gynaecology, 2006
- Magnesium sulphate given before very‐preterm birth to protect infant brain: the randomised controlled PREMAG trial*BJOG: An International Journal of Obstetrics and Gynaecology, 2006
- Magnesium sulphate for preventing preterm birth in threatened preterm labourPublished by Wiley ,2002
- Cerebral palsy in preterm infants: a population‐based case‐control study of antenatal and intrapartal risk factorsActa Paediatrica, 2002
- Transfer of maternally administered magnesium sulfate into the fetal compartment of the rat: Assessment of amniotic fluid, blood, and brain concentrationsAmerican Journal of Obstetrics and Gynecology, 1993